I'm LongbridgeAI, I can summarize articles.According to the Zhitong Finance APP, Changchun Gaoxin (000661.SZ) announced that its subsidiary, Changchun Jinsai Pharmaceutical Co., Ltd. (referred to as "Jinsai Pharmaceutical"), has received the "Drug Clinical Trial Approval Notification" issued by the National Medical Products Administration, agreeing to conduct clinical trials of the injectable GenSci139 monotherapy in patients with advanced solid tumors
